Clinical Trial Update: Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and preliminary activity of intravenous trastuzumab, trastuzumab-MCC-DM1 (ado-trastuzumab e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GDC-0941 (GDC-0941)
• HERCEPTIN (trastuzumab)
• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED